骨靶向纳米颗粒治疗骨质疏松症研究进展  

Advances in bone-targeted nanoparticles for the treatment of osteoporosis

作　　者：程渊 张人伟 杨浩东 岳斌 张良童 张有良 黄委委 林德民 刘东 谢兴文 CHENG Yuan;ZHAN Renwei;YANG Haodong;YUE Bin;ZHANG Liangtong;ZHANG Youliang;HuangWeiwei;LIN Demin;LIU Dong;XIE Xingwen(Gansu University of Chinese Medicine,Lanzhou 730000,China;Affiliated Hospital of Gansu University of Chinese Medicine,Lanzhou 730000,China)

机构地区：[1]甘肃中医药大学,甘肃兰州730000 [2]甘肃中医药大学附属医院,甘肃兰州730000

出　　处：《中国骨质疏松杂志》2025年第3期435-439,共5页Chinese Journal of Osteoporosis

基　　金：国家自然科学基金(82160911,82374491);甘肃省拔尖领军人才项目[省委人才小组发(2021)2号]。

摘　　要：骨质疏松症(osteoporosis,OP)是一种退行性骨骼疾病,其特征是骨量减少和骨组织微结构恶化,增加了骨骼的脆弱性和骨折的风险。目前临床上用于治疗OP的药物主要分为骨吸收抑制剂和骨形成促进剂两种类型,虽然具有一定疗效,但大多数抗OP药物并没有靶向地递送到骨组织中,同时会产生一定的毒副作用。近年来,纳米颗粒骨靶向治疗OP具有载药量大、靶向性强、易于修饰和较好的生物相容性等特点,可以有效克服传统疗法的不足,在OP的治疗中得到了广泛的应用。为此,本文综述了近年来有关骨靶向纳米颗粒治疗OP的进展,为探索基于骨靶向纳米颗粒干预OP的治疗策略提供理论依据。Osteoporosis(OP)is a degenerative bone disease characterized by decreased bone mass and deterioration of bone tissue microarchitecture,which increases the fragility of bones and the risk of fractures.Currently,the drugs used in the clinical treatment of OP are mainly divided into two types:bone resorption inhibitors and bone formation enhancers.Although they have certain efficacy,most anti-OP drugs are not delivered to the bone tissues in a targeted manner,and at the same time,they can produce certain toxic side effects.In recent years,nanoparticle bone-targeted therapy,which is characterized by large drug loading capacity,strong targeting,easy modification and taught biocompatibility,can effectively overcome the shortcomings of traditional therapies and has been widely used in the treatment of OP.For this reason,this paper reviews the progress of bone-targeted nanoparticle-based treatment of OP in recent years to provide a theoretical basis for exploring the therapeutic strategy of nanoparticle-based intervention in OP.

关 键 词：骨质疏松症 骨靶向治疗 纳米颗粒 综述 

分 类 号：R681[医药卫生—骨科学]